iNtRON Biotechnology, Inc. Stock

Equities

A048530

KR7048530000

Biotechnology & Medical Research

End-of-day quote Korea S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
6,970 KRW -1.13% Intraday chart for iNtRON Biotechnology, Inc. +1.31% -20.62%

Financials

Sales 2022 14.01B 10.11M 13.92M Sales 2023 9.59B 6.92M 9.53M Capitalization 291B 210M 290M
Net income 2022 5.71B 4.12M 5.68M Net income 2023 -9.7B -7M -9.64M EV / Sales 2022 13.8 x
Net cash position 2022 76.58B 55.29M 76.12M Net cash position 2023 56.78B 41M 56.44M EV / Sales 2023 24.5 x
P/E ratio 2022
-23,726 x
P/E ratio 2023
-30.1 x
Employees 81
Yield 2022 *
-
Yield 2023
1.14%
Free-Float 81.28%
More Fundamentals * Assessed data
Dynamic Chart
INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer CI
INtRON Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Basilea Pharmaceutica Signs Evaluation License, Option Deal With Korea's iNtRON MT
INtRON Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022. CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022. CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022. CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022. CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022. CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022. CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022. CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022. CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on December 2, 2022, has expired with 324,118 shares, representing 0.97% for KRW 2,997.54 million. CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on December 2, 2022, has expired with CI
More news
1 day-1.13%
1 week+1.31%
Current month-4.13%
1 month-4.13%
3 months-7.93%
6 months+17.54%
Current year-20.62%
More quotes
1 week
6 600.00
Extreme 6600
7 110.00
1 month
6 600.00
Extreme 6600
7 510.00
Current year
6 600.00
Extreme 6600
9 300.00
1 year
5 250.00
Extreme 5250
12 470.00
3 years
5 250.00
Extreme 5250
27 350.00
5 years
5 250.00
Extreme 5250
34 500.00
10 years
5 250.00
Extreme 5250
46 700.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 01-12-02
Chief Executive Officer 55 00-05-11
Director/Board Member 55 -
Members of the board TitleAgeSince
Director/Board Member 59 -
Chief Executive Officer 55 00-05-11
Chief Executive Officer 52 01-12-02
More insiders
Date Price Change Volume
24-04-30 6,970 -1.13% 134,078
24-04-29 7,050 +2.47% 119,835
24-04-26 6,880 -0.29% 61,742
24-04-25 6,900 -1.57% 48,466
24-04-24 7,010 +0.43% 49,983

End-of-day quote Korea S.E., April 29, 2024

More quotes
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A048530 Stock